Biotie Completes Planned Portfolio Review Biotie Therapies

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 24, 2013 at 2:15 AM

Biotie Completes Planned Portfolio Review

Biotie Therapies Corp. Stock Exchange Release 24 September 2013 at 9.00 a.m Biotie Completes Planned Portfolio Review Biotie Therapies Corp., a specialized drug development company focused on neurodegenerative and psychiatric disorders, today announces the outcome of its planned portfolio review following its success earlier in the year with the approval and launch of Selincro® in Europe by H. Lundbeck A/S ("Lundbeck") and the exercise by UCB S.A. ("UCB") of its license for tozadenant (SYN115), for which Biotie received a USD 20 million milestone. The review establishes the best way for Biotie to maximize value from its current products and introduces a new strategy under which the company will use its relatively strong financial position to seek additional pipeline opportunities, including those that it could potentially develop itself through to regulatory approval and beyond. For the past few years, Biotie has successfully operated a strategy built around search, profile and partner to bring novel products to market. This strategy has to date delivered development and commercialization deals for: * Selincro®, used to treat alcohol dependence, with Lundbeck, which introduced the product in Europe earlier in 2013. Biotie is eligible to receive milestones for launches in further key European markets in 2013 and 2014 and to receive royalties and further milestone payments; and * tozadenant (SYN115) for Parkinson's disease, with UCB, which is being prepared for Phase 3 development. Under the terms of a subsequent agreement Biotie will conduct the phase 3 development in return for additional payments from UCB relating to defined development, regulatory and commercial milestones. NRL-1, a proprietary intranasal formulation of diazepam that is being developed to treat patients with epilepsy to manage the bouts of acute and repetitive seizures they experience, became part of Biotie's development portfolio in June 2013 when the Company signed an exclusive option to acquire Neurelis, Inc., a private U.S. company developing products for epilepsy and other disorders of the central nervous system. The purchase of an option to acquire Neurelis and its lead product NRL-1 has given Biotie an important new development opportunity. Biotie is now actively engaged in conducting further manufacturing and pre-clinical work with the product and expects to exercise the option in the first half of 2014 following completion of the work and discussions with the FDA. The treatment of acute and repetitive seizures is an area where there are currently limited treatment options, particularly for adolescent and adult patients. Biotie believes that the introduction of NRL-1 in a patient friendly intra-nasal applicator will give it access to a significant commercial opportunity in the U.S. that could be accessed via a small, specialist sales force, which Biotie could potentially establish. The successful development and commercialization of NRL-1 will allow Biotie to generate enhanced shareholder value and, as a result of the portfolio review, further opportunities of this kind will now be sought. The portfolio review has also led to the decision to conduct a Phase 2 proof of concept study for primary sclerosing cholangitis, a rare fibrotic disease of the liver affecting young adults, with BTT-1023. The Company is in advanced discussions for non-dilutive co-funding for the study. Discussions for a potential partnership for SYN120, which is being developed for the treatment of Alzheimer's disease and other cognitive disorders, are at an advanced stage. The trial for nepicastat (SYN117), in the treatment of cocaine dependency, which began in May 2013 and is being funded by the U.S. National Institute of Drug Abuse, is continuing to recruit, with results being expected in approximately two years. Timo Veromaa, Biotie's President and CEO commented, "As a result of a detailed portfolio review we now have a clear strategy for each of our current products that we believe will allow us to enhance shareholder value. We will also utilize our relatively strong financial position to identify new assets that will further strengthen our portfolio and that we could potentially develop all the way to the market." Turku, 24 September 2013 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8911 e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com About Biotie Biotie is a specialized drug development company focused primarily on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependency, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease in collaboration with UCB Pharma S.A.. Biotie also has exclusive rights through an option to acquire Neurelis Inc., which includes NRL-1, an intranasal formulation of diazepam for epileptic seizure management. Biotie plans to seek further opportunities of this kind to generate a strong portfolio of products. Biotie's shares are listed on NASDAQ OMX Helsinki. [HUG#1731011]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ONLYOFFICE 10.0 Boosts AI and Security Features

A Fresh Look at ONLYOFFICE 10.0's Game-Changing Update Outta the gates swinging, ONLYOFFICE dropped their latest 10.0 update. This one ain't just your average software facelift—it's packing some serious heat with AI enhancements, brand spanking new modular apps, and beefed-up security features that'll make anyone dealing with sensitive data breathe a little easier. AI...

tm:rw Revolutionizes Retail with Live TikTok Studios

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

AI Revenue Missteps Shake Semiconductor Stocks

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

Tchah Sup Kim: A Retrospective at KCCNY in 2026

A Glimpse into Tchah Sup Kim's Legacy Stumble into the world of Tchah Sup Kim (1940–2022) this fall at the Korean Cultural Center New York. Kim's posthumous retrospective, "The Key to a New World," brings together over 130 of his works alongside archival materials, offering a comprehensive dive into a mind that spent decades between New York and Korea. The exhibit,...

Kexing Biopharm Expands Global Reach at CPHI Milan

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...

NOARK: Powering Data Centers with Global-Local Approach

The High-Stakes Race for Data Center Power These days, if you're not talking about data centers, you're probably a step behind the curve. AI's explosive growth is pushing data center developments across North America like never before. Larger campuses, hefty power densities—it's all happening at a pace that's got everyone scrambling. For folks like NOARK Electric, this...

CenterPoint Deploys Crews for Hurricane Aid Relief

CenterPoint’s Commitment Amidst Crisis Now, when a hurricane slams into the coast, it’s go time for everyone in the game. CenterPoint Energy, never one to sit on the sidelines, is showing up with a hefty squad to help fix the mess left by Hurricane Isaias. A robust 355-strong team is heading out to assist with power restoration down there in Florida. This isn’t just...

New Docs Spotlight Psychiatry on World Mental Health Day

Unmasking Mental Health on the Global Stage Hold onto your hats, folks. The Scientology Network is cranking up the heat this World Mental Health Day. On October 10, they’re rolling out a program that puts the spotlight on CCHR’s crusade against what they see as dark forces in the psychiatric industry. It’s a marathon of documentaries that dives into allegations of...

Arrvel's Thermal Printers: Aiming at E-Com Sellers

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...

AI in Music: CITY JAM Focuses on Human Creativity

Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...